Recurrent Myelodysplastic Syndrome Recruiting Phase 1 Trials for Cytarabine (DB00987)

Indication	Status	Phase
DBCOND0113509 (Recurrent Myelodysplastic Syndrome)	Recruiting	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04375631	CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia	Treatment	Cladribine (DB00242) Cyclophosphamide (DB00531) Cyclosporine (DB00091) Cytarabine (DB00987) Filgrastim (DB00099) Fludarabine (DB01073) Idarubicin (DB01177) Mitoxantrone (DB01204) Mycophenolate mofetil (DB00688) Mycophenolic acid (DB01024)
NCT04250051	Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia	Treatment	Cytarabine (DB00987) Filgrastim (DB00099) Fludarabine (DB01073) Ivosidenib (DB14568)